stars 1 stars 2 stars 3

At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms. We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide. To learn more about us, visit Our privacy statement can be found here:

View Top Employees from BioNTech SE
Ticker BNTX
Revenue $124 million
Funding $1.3 billion
Employees 3,969 (2,765 on RocketReach)
Founded 2008
Address An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
Phone +49 4961 319084
Fax +49 6131 9084390
JavaScript, HTML, Twitter +82 more (view full list)
Category Biotechnology, Biotechnology Research, Pharmaceuticals, Biopharma, Personalized Oncology Therapy, Healthcare, Drug Discovery, Health Care, Science and Engineering, Pharmaceutical
Web Rank 671478
Keywords biontech, biontech ag, biontech startup, biontech founders, bisonteck
Competitors Dendreon, Juno Therapeutics, Inc., Kite Pharma, Nektar Therapeutics, Seagen
SIC 873, 87
NAICS 32541, 3254, 325, 32, 54, 541

BioNTech SE Questions

The BioNTech SE annual revenue was $124 million in 2023.

Thomas Wohn is the Vice President Business Projects of BioNTech SE.

2,765 people are employed at BioNTech SE.

BioNTech SE is based in Mainz, Rhineland-Palatinate.

The NAICS codes for BioNTech SE are [32541, 3254, 325, 32, 54, 541].

The SIC codes for BioNTech SE are [873, 87].

Top BioNTech SE Employees

How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
G2Crowd Trusted
300K+ Plugin Users